|
Re: ZHCLF
|
1
|
Zenith Epigenetics
|
Jan 03, 2024 09:36PM
|
|
Re: ZHCLF
|
1
|
Zenith Epigenetics
|
Jan 03, 2024 05:13PM
|
|
Re: Happy New Years
|
6
|
Resverlogix Corp.
|
Dec 30, 2023 05:35PM
|
|
The crick didn’t rise, here’s the presentation, finally!
|
5
|
Zenith Epigenetics
|
Oct 27, 2023 05:31PM
|
|
Re: Could it be
|
2
|
Zenith Epigenetics
|
Oct 27, 2023 11:05AM
|
|
Re: Notice anything different about #11
|
4
|
Zenith Epigenetics
|
Oct 26, 2023 10:10PM
|
|
Re: ACCORDING TO "GlobalData" https://www.globalda...
|
2
|
Resverlogix Corp.
|
Oct 26, 2023 09:08AM
|
|
Re: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophy
|
2
|
Resverlogix Corp.
|
Oct 04, 2023 01:49PM
|
|
Can we seek funding for this?
|
3
|
Resverlogix Corp.
|
Oct 04, 2023 07:59AM
|
|
Re: Resverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetes
|
5
|
Resverlogix Corp.
|
Aug 29, 2023 06:49PM
|
|
Re: Review of ZCC history
|
2
|
Zenith Epigenetics
|
Aug 29, 2023 10:37AM
|
|
Re: Long covid trials
|
2
|
Resverlogix Corp.
|
Aug 01, 2023 09:53AM
|
|
Re: Long Covid remains a big challenge
|
2
|
Resverlogix Corp.
|
Jul 25, 2023 01:02PM
|
|
Re: Long Covid remains a big challenge
|
|
Resverlogix Corp.
|
Jul 25, 2023 08:51AM
|
|
Re: Long Covid remains a big challenge
|
2
|
Resverlogix Corp.
|
Jul 25, 2023 07:34AM
|
|
Re: Additional Reports of Exempt Distribution
|
2
|
Zenith Epigenetics
|
Jul 25, 2023 07:31AM
|
|
Re: While we fiddle
|
3
|
Resverlogix Corp.
|
Jul 20, 2023 10:52AM
|
|
Re: For what it’s worth
|
4
|
Zenith Epigenetics
|
Jul 20, 2023 08:35AM
|
|
While we fiddle
|
5
|
Resverlogix Corp.
|
Jul 20, 2023 08:10AM
|
|
Re: For what it’s worth
|
3
|
Zenith Epigenetics
|
Jul 20, 2023 08:04AM
|
